In addition to the transfection studies, treatment of pancreatic cancer cells with canertinib and afatinib at the indicated concentrations also resulted in significant inhibition of phospho-STAT1 and decrease of MUC4 mucin protein expression. The gene discussed is MUC5AC; the disease is familial pancreatic carcinoma.